Designer mucin-responsive nanomedicine for enhanced solid tumour penetration and therapy.
Yu Na N, Gong Ningqiang N, Liu Juan J, Zhong Haiping H et al.
While nanomedicines hold great promise for solid tumour therapy, their penetration and access to tumour cells is limited by large glycosylated proteins called mucins that are enriched in the tumour microenvironment. Here we show that mucins induce the disassembly of self-assembled mPEG-polyester micellar nanoparticles into smaller unimers. Leveraging this finding, we designed a mucin-responsive, paclitaxel-conjugated nanomedicine (mrPNM) whose unimers are capable of escaping the mucin-binding barrier. Following intravenous injection, this designer mucin-responsive nanomedicine exhibited markedly deeper penetration than the mucin-nonresponsive nanomedicine and albumin, resulting in 3.9- and 1.5-fold increases in tumour cell delivery, respectively, in a pancreatic mouse tumour model. The mrPNMs also achieved superior tumour growth inhibition compared to both the mucin-nonresponsive nanomedicine and Abraxane, the FDA-approved nanoparticle albumin-bound paclitaxel, in three solid tumour models. The mucin-responsive nanomedicine platform could provide a general strategy for improving the treatment of solid tumours.